Clinical activity of eribulin in advanced desmoplastic small round-cell tumor.

Abstract

Desmoplastic small round-cell tumor is a rare but highly aggressive tumor occurring mainly in adolescents and young adults. Prolonged progression-free survival has been documented in patients who have undergone aggressive multimodality therapy - that is, multiagent intensive chemotherapy, debulking surgery, and radiation therapy. Eribulin is a microtubule-dynamics inhibitor, and it has recently been shown to be active in liposarcomas. In preclinical models, eribulin activities have also been shown to occur in Ewing's sarcoma cell lines, rhabdomyosarcomas and osteosarcomas. In this study, we report three cases of male patients suffering from desmoplastic small round-cell tumor and the clinical response to eribulin in two of them.

• Authors: Sheik Emambux, Michele Kind, Francois Le Loarer, Maud Toulmonde, Eberhard Stoeckle, Antoine Italiano
• Journal: Anti-cancer drugs (Anticancer Drugs) Vol. 28 Issue 9 Pg. 1053-1055 (10 2017) ISSN: 1473-5741 [Electronic] England
• PMID: 28863036 (Publication Type: Case Reports, Journal Article)

Chemical References

• Furans
• Ketones
• eribulin

Topics

• Adult
• Desmoplastic Small Round Cell Tumor (drug therapy, pathology)
• Disease-Free Survival
• Furans (therapeutic use)
• Humans
• Ketones (therapeutic use)
• Male
• Pancreatic Neoplasms (drug therapy, pathology)
• Peritoneal Neoplasms (drug therapy, pathology)